fludarabine has been researched along with abt-199 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 8 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JR; O'Brien, SM; Porter, DL | 1 |
| Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP | 1 |
| Bendell, J; Brown, JR; Derks, IA; Eichhorst, B; Eldering, E; Fernandes, SM; Filvaroff, EH; Garrick, B; Hallek, M; Hege, K; Kater, AP; Kersten, MJ; Michot, JM; Reinhardt, HC; Rodríguez, MS; Ter Burg, J; Thijssen, R; Trowe, T; van Bochove, GG; van Kampen, RJ | 1 |
| Brown, JR; Hallek, MJ; Pagel, JM | 1 |
| Chauffaille, MLLF; Fonseca, ARBMD; Goncalves, MV; Guedes, NR; Lacerda, MP; Pereira, AD; Rodrigues, CA; Yamakawa, PE; Yamamoto, M | 1 |
| Wierda, WG | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Suzumiya, J; Takizawa, J | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Adams, JM; Anderson, MA; Blombery, P; Carney, DA; Chen, X; Dengler, MA; Handunnetti, SM; Huang, DCS; Lew, TE; Lin, VS; Nguyen, T; Panigrahi, A; Roberts, AW; Seymour, JF; Tam, CS; Thompson, ER; Wei, AH; Westerman, DA | 1 |
| Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM | 1 |
| Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B | 1 |
| Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C | 1 |
4 review(s) available for fludarabine and abt-199
| Article | Year |
|---|---|
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
6 trial(s) available for fludarabine and abt-199
| Article | Year |
|---|---|
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Topics: Bridged Bicyclo Compounds, Heterocyclic; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Nuclear Proteins; Purines; Pyrazines; Quinazolinones; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Vidarabine | 2016 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Myelopoiesis; Myeloproliferative Disorders; Neoplasms, Second Primary; Sulfonamides; Vidarabine | 2022 |
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Transplantation, Homologous; Vidarabine | 2021 |
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab | 2023 |
4 other study(ies) available for fludarabine and abt-199
| Article | Year |
|---|---|
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine | 2015 |
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Sulfonamides; Vidarabine | 2017 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Topics: Alkylating Agents; AMP-Activated Protein Kinases; Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Caspase 3; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Nucleosides; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; STAT5 Transcription Factor; Sulfonamides; Transplantation Conditioning; Vidarabine | 2022 |